Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial

Summary: Abivax is a medical company that made a new drug called obefazimod to treat a painful stomach disease called ulcerative colitis. In a big test, the drug worked amazingly well, helping about half of the patients get much better. This success rate is higher than many other drugs on the market.

However, the company's stock price suddenly dropped by 28%. This happened because a few patients taking the highest dose of the drug developed cancer. Even though doctors and experts say these few cancer cases are normal for this specific group of sick patients and are "not worrisome," investors still got scared and sold their stock. Despite the stock crash, Abivax plans to ask the FDA to approve the drug later this year.

For more details, see rssapp-fiercebiotech-com at fiercebiotech.com/biotech/abivax-stock-crashes-cancer-cases-overshadow-stellar-efficacy-ulcerative-colitis-phase-3 (opens in new tab)